Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy.
about
Low dose versus high dose stavudine for treating people with HIV infectionIncidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.HIV-1 Vpr induces adipose dysfunction in vivo through reciprocal effects on PPAR/GR co-regulation.Long-term ritonavir exposure increases fatty acid and glycerol recycling in 3T3-L1 adipocytes as compensatory mechanisms for increased triacylglycerol hydrolysis.Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysisGlyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue.Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function.Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.Lipodystrophy: pathophysiology and advances in treatmentHypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapyAdverse effects of antiretroviral therapy: focus on orofacial effects.Human immunodeficiency virus endocrinopathy.Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalitiesDietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era.Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemiaDepot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophyViral mechanisms of adipose dysfunction: lessons from HIV-1 VprBody composition and metabolic changes in HIV-infected patientsCellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.Leptin in relation to the lipodystrophy-associated metabolic syndromeLipolytic Rate Associated With Intramyocardial Lipid in an HIV Cohort Without Increased Lipolysis.Toxic metabolic syndrome associated with HAART.Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy.Impact of age on markers of HIV-1 diseaseStrategies in the treatment of HIV-1-associated adipose redistribution syndromes.Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients.Metabolic syndrome risks of cardiovascular disease: differences between HIV-positive and HIV-negative?Decreased respiratory quotient in relation to resting energy expenditure in HIV-infected and noninfected subjects.The effect of recombinant human growth hormone with or without rosiglitazone on hepatic fat content in HIV-1-infected individuals: a randomized clinical trial.Growth and puberty in children with HIV infection.Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAARTExploring the pathophysiology behind the more common genetic and acquired lipodystrophies.An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes.HIV1-viral protein R (Vpr) mutations: associated phenotypes and relevance for clinical pathologies.Adipose Tissue in HIV Infection.Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.Regulation of adipocyte lipolysis by degradation of the perilipin protein: nelfinavir enhances lysosome-mediated perilipin proteolysis.Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy.
P2860
Q24242088-D83F44EB-A9B7-444D-BF8D-74B53B236AB9Q31146395-53E9A21A-8866-4485-8C7A-D46A2111CBC0Q33562238-E2674124-29B1-40E6-8D55-0FA6048B2AB9Q33848305-274C733C-C55E-4689-8470-465B75D08379Q34312147-122799FD-EABB-4065-8F63-D5AC0EE271FDQ34503338-07719DF7-9FF0-423D-ABFE-666DB0FA7E00Q34512603-47C0E483-6CC9-40CD-BBE4-2924C25E3252Q34564973-53A4F934-AB79-49E0-9F3E-EC9482AEF8A7Q35101789-969FA598-C6F1-4C10-AE16-BAF3F5799BC9Q35148915-C0E051D2-7D0B-4FEB-A524-C7A7E691EA3DQ35176441-3A9F58FE-7F90-4C50-B659-E44490D80D91Q35194049-02974689-AF1D-40F7-AE2C-3D21EB850BB2Q35194451-3EA12CD4-DE7B-48C5-8784-F459A8558DE2Q35352448-5F44D73F-A055-4827-84C0-52B79C685D29Q35369261-A73D46FA-78DD-49B6-BCE6-1FE9D9D4BCC5Q35370152-D590DAE5-D34D-4759-831D-B1B81460B287Q35384143-886DCE95-8FD1-45AB-A245-2CD0227B676EQ35400307-4A5AAA55-F23E-450D-905E-181895651D3CQ35834850-90CB0582-3E8B-4052-9881-EF75FA38624BQ35949965-A3C2CDF0-338D-4CEE-BE98-E9455577308AQ36011828-719102BE-CFD1-48C2-8E60-B21D7626B508Q36049195-6AC2DA6F-3D32-4A5B-AE71-879CDB79011DQ36431659-E8EA3189-5448-4951-B5F7-C8864F3AD071Q36544924-D593909D-1DF5-423F-BA91-0028B45888B5Q36663879-87F342F7-F7C1-4B5F-81D8-9C2B9EC74959Q36763762-1869A32B-544B-4B92-8A2B-B7BE751CB03DQ36909274-A78B1202-1F63-45B5-B83F-8F1378FEBC40Q36951647-220343D4-DB29-418A-9865-4C5BE5B7F813Q37153502-A04A3B7F-FC2B-4809-9D67-E27524633E21Q37214557-0B34AB0A-588A-4E6A-B304-2F1A7AD3489CQ37415273-7497AF32-E3BA-48C2-B8B4-AC01C50EE9A1Q37428510-B5E45443-1FCC-4E01-BB95-80FCEE0D041BQ37604169-2DD4C949-37D2-4364-B926-705C424772CAQ38155007-64B5709A-354C-4B49-833C-D5E78FE17D74Q38220651-84ADD090-F2F7-4CC5-917B-4DC9153A1C5DQ38855423-A51E6966-2A76-416E-B247-1AE23C70CB6EQ40038736-00EBF9EC-817A-4DC6-AFAD-1313476BC4CFQ42176233-695EE405-60D2-4C7A-97BA-6B596149739BQ42512370-8775CFAF-0207-473F-B72A-1E58750B7088Q43035535-0287633C-B382-4B22-B40F-B01F3A7CC99B
P2860
Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Increased rates of lipolysis a ...... active antiretroviral therapy.
@en
type
label
Increased rates of lipolysis a ...... active antiretroviral therapy.
@en
prefLabel
Increased rates of lipolysis a ...... active antiretroviral therapy.
@en
P2093
P356
P1433
P1476
Increased rates of lipolysis a ...... active antiretroviral therapy.
@en
P2093
Colleen Hadigan
Jessica Rabe
Steven Grinspoon
Sudhir Borgonha
Vernon Young
P304
P356
10.1053/META.2002.34704
P577
2002-09-01T00:00:00Z